Publication Highlights

• Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia 2018. PMID: 29249822
• Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res. PMID: 29061640
• Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. Biol Blood Marrow Transplant. PMID: 29079457
• Bendamustine, lenalidomide, and dexamethasone (BRD) are highly effective with durable responses in relapsed multiple myeloma. American Journal of Hematology. 2015. PMID: 26331432
• Allosteric Communication across STAT3 Domains Associated with STAT3 Function and Disease-Causing Mutation. J Mol Biol. 2016. PMCID: PMC4767637
• Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomized, phase 2 trial. Lancet. 2016.
• Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Curr Hematol Malig Rep. 2016.
• Treatment of Multiple Myeloma: Finding the Right Combination. Oncology (Williston Park). 2016.
• Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy. Am Soc Clin Oncol Educ Book. 2016.
• Heavy/light chain ration normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. Br J Haematol. 2016.
• Oncology in primary care. Lippincott Williams & Wilkins 2013. Chapter 70, HIV and other immunosuppression-related malignancies. ISBN: 978-1-4511-1149-1.
• How to think about risk in myeloma. Clin Lymphoma Myeloma Leuk. 2016.
• A Phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Cancer. 2016.
• POINT: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma. Oncology (Williston Park). 2016.
• Role of SUMO Activating Enzyme in Cancer Stem Cell Maintenance and Self-renewal. Nat Commun. 2016.
• Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma, BBMT 2017.
• Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis, BBMT 2016. PMCID: PMC5090978
• Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. Br J Haem, 2017. PMCID: PMC5154782
• Study design for vulnerable older adults with multiple myeloma. J Geriatr Oncol 2017. PMID: 28412160